Aims This study aimed to elucidate the risk for stroke and systemic embolism (SE) in patients with atrial fibrillation and heart failure (HF) according to HF type. Methods and results A total of 10 780 patients with atrial fibrillation were enrolled in a multicentre prospective registry and ...
2011 - Rivaroxaban reduced stroke and systemic embolism compared with warfarin in nonvalvular AF ACP Journal ClubKlein, Liviu
EchocardiographyElectrocardiography, AmbulatoryPrognosisIncidenceRisk AssessmentRheumatic MS is a common cause of stroke and systemic embolism in developing countries... G Karthikeyan,R Ananthakrishnan,N Devasenapathy,... - 《American Journal of Cardiology》 被引量: 40发表: 2014年 Atheromatous disease of ...
The primary endpoint, stroke or systemic embolism, was reduced by 21% in the apixaban group relative to the warfarin group. Major bleeding (primary safety endpoint) was reduced by 31%, and total mortality by 11% in apixaban treated patients. In the AVERROES trial, apixaban was compared to ...
Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation. NICE technological appraisal guidance 249. March 2012.Ahmad Y; Lip GY.Dabigatran etexilate for the preventionof stroke and systemic embolism in atrial fibrillation :NICE guidance.Heart.2012.1404-1406...
European Society of Cardiology Congress 2011 The oral factor Xa inhibitor apixaban was superior to warfarin for the prevention of both stroke and systemic embolism in patients with atrial fibrillation, new study results indicated.
The pivotal, randomized, phase III clinical trial that established the efficacy and safety of dabigatran in comparison to dose-adjusted warfarin for the prevention of stroke and systemic embolism in patients with non-valvular AF, the “RE-LY” (Randomized Evaluation of Long-Term Anticoagulation Thera...
with atrial fibrillation, fixed-dose oral ximelagatran was at least as effective as well-controlled warfarin for prevention of stroke and systemic embolism.do... None - 《Lancet》 被引量: 2012发表: 2003年 Secondary stroke prevention with ximelagatran versus warfarin in patients with atrial fibrillati...
et al. Oral direct thrombin inhibitor AZD0837 for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: a phase II study of AZD0837 in patients who are appropriate for but unable or unwilling to take vitamin K antagonist therapy. Thromb. Res. 127, ...
摘要: In this study, all-cause, stroke/systemic embolism 关键词:elderly nonvalvular atrial fibrillation oral anticoagulants apixaban rivaroxaban dabigatran warfarin stroke systemic embolism major bleeding health-care costs 年份: 2018 收藏 引用 批量引用 报错 分享 ...